Skip to main content

Advertisement

Table 4 JCPyV DNA detection in samples collected from 18 CD patients during 1 year of infliximab

From: Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study

Plasma (log10 gEq/mL)
Time* t0 t1 t2 t3 t4
JCPyV+ / JCPyV- 6 / 12 7 / 11 5 / 13 5 / 13 5 / 13
median JCPyV load (range) 4.93 5.30 3.08 3.63 4.24
(3.06-6.58) (3.78-5.59) (2.58-6.11) (2.76-5.35) (3.92-5.54)
Urine (log10 gEq/mL)
JCPyV+ / JCPyV- 6 / 12 10 / 8 6 / 12 6 / 12 6 / 12
median JCPyV load (range) 6.30 6.12 5.85 7.47 6.70
(4.85-8.85) (3.17-8.37) (4.30-8.15) (5.63-9.39) (3.85-7.85)
Ileum (log10 gEq/10 6 cells)
JCPyV+ / JCPyV- 10 / 8    7 / 11 4 / 14
median JCPyV load (range) 4.29    5.85 5.07
(3.54-6.57)    (4.34-8.48) (3.81-7.15)
Colon rectum (log10 gEq/10 6 cells)
JCPyV+ / JCPyV- 8 / 10    4 / 14 4 / 14
median JCPyV load (range) 3.66    4.85 4.25
(3.10-4.67)    (3.52-6.08) (3.38-4.78)
  1. *We collected 90 plasma and 90 urine samples from CD patients at the following times of sampling: at the time of recruitment (t0) and at 4, 8, 12 and 16 months from t0 (t1, t2, t3, and t4 respectively). 54 ileal and 54 colon–rectal biopsies were recruited at t0, t3 and t4 within the same cohort.